1. Indications and Usage
\nRheumatoid Arthritis (RA): Treatment of adult patients with moderately to severely active RA, in combination with methotrexate (MTX) or as monotherapy.
\nJuvenile Idiopathic Arthritis (JIA): Treatment of patients 2 years of age and older with polyarticular JIA.
\nPsoriatic Arthritis (PsA): Treatment of adult patients with active PsA.
\nAnkylosing Spondylitis (AS): Treatment of adult patients with active AS.
\nPlaque Psoriasis: Treatment of adult and pediatric patients (6 years and older) with moderate to severe chronic plaque psoriasis.
\n2. Dosage and Administration
\nRoute of Administration:
\nFor Subcutaneous Injection ONLY.
\nRecommended Dosage:
\nAdults (RA, PsA, AS): 50 mg once weekly OR 25 mg twice weekly (approximately 72 to 96 hours apart).
\nAdults (Plaque Psoriasis): 50 mg twice weekly for up to 12 weeks, followed by 50 mg once weekly.
\nPediatric Patients (JIA): 0.8 mg\/kg per dose (up to a maximum of 50 mg per week), administered once weekly or as two divided doses of 0.4 mg\/kg twice weekly.
\nAdministration:
\nPatients may self-inject if their physician determines it is appropriate and they receive proper training.
\n3. Mechanism of Action
\nTNF Receptor Antagonist:
\nEtanercept is a dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) TNF receptor linked to the Fc portion of human IgG1.
\nBlocking Signaling:
\nIt binds with high affinity to soluble TNF-\u03b1 and lymphotoxin-\u03b1 (LT-\u03b1, also known as TNF-\u03b2), preventing them from interacting with cell surface TNF receptors. This neutralizes the biological activity of TNF, thereby reducing inflammation and tissue damage.
\n4. Safety and Warnings
\nSerious Infections (Boxed Warning):
\nPatients are at increased risk for serious infections (e.g., Tuberculosis, bacterial sepsis, invasive fungal infections) that may lead to hospitalization or death. Screen for latent TB prior to initiation.
\nMalignancy:
\nIncreased risk of malignancies, particularly lymphoma and leukemia. Cases of hepatosplenic T-cell lymphoma (HSTCL) have been reported in adolescents and young adults.
\nHepatitis B Reactivation:
\nCases of HBV reactivation have occurred in carriers. Monitor liver function and HBV viral load.
\nNervous System Events:
\nNew or worsening central or peripheral nervous system demyelinating disorders (e.g., Multiple Sclerosis, optic neuritis) have been reported.
\nHematologic Events:
\nRare cases of pancytopenia, including aplastic anemia, have been reported.
\nLive Vaccines:
\nAvoid concurrent use with live vaccines.
\n5.Drug Interactions
\nAnakinra \/ Abatacept:
\nConcomitant use is not recommended due to an increased risk of serious infections and no additional clinical benefit.
\nTocilizumab:
\nConcomitant use is not recommended due to increased risk of serious infections.
\n6.Adverse Reactions
\nMost Common:
\nInjection site reactions (rash, pruritus, erythema, pain, swelling) are the most frequent adverse event. Other common reactions include upper respiratory tract infections, headache, and diarrhea.
\n7.Pharmaceutical Information
\nChemical Composition:
\nActive Ingredient: Etanercept.
\nAvailable Strength: 25 mg, 50 mg prefilled syringes or pens.
\nAppearance: Clear to slightly opalescent, colorless to pale yellow liquid.
\nStorage: Store at 2\u00b0C to 8\u00b0C (36\u00b0F to 46\u00b0F) in the original carton to protect from light.<\/p>\n","protected":false},"excerpt":{"rendered":"
Brand Name:\u6069\u5229 \u00ae\uff08Enbrel\u00ae\uff09
\nGeneric Name: Etanercept Solution
\nStrength: 0.94 mL : 50 mg per pre-filled syringe
\nManufacturer: Pfizer Manufacturing Belgium NV
\nMarketing Authorization Holder: Pfizer Europe MA EEIG. Domestic filing entities are Pfizer Investment Co., Ltd. and Pfizer Pharmaceuticals Ltd.
\nApproval Date in China: February 2010
\nRegistration Number: \u56fd\u836f\u51c6\u5b57 SJ20170049
\nStorage: Store under refrigeration at 2\u20138\u00b0C (36\u201346\u00b0F). Do not freeze. Keep in the original carton to protect from light. Once removed from refrigeration, the product may be stored at room temperature (up to 25\u00b0C\/77\u00b0F) for a single period of up to 14 days, protected from light. If not used within 14 days, return to refrigeration. Refer to the package insert for detailed handling instructions.<\/p>\n
Price&Cost:Contact Us now for the best price of Etanercept Solution\uff08Enbrel\uff09<\/p>\n
<\/p>\n","protected":false},"featured_media":4033,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[81],"product_cat":[25],"product_tag":[],"class_list":["post-4032","product","type-product","status-publish","has-post-thumbnail","product_brand-pfizer","product_cat-injection","first","instock","shipping-taxable","product-type-simple"],"yoast_head":"\n